Elanco Animal Health (NYSE:ELAN) Upgraded by JPMorgan Chase & Co. to “Overweight” Rating

JPMorgan Chase & Co. upgraded shares of Elanco Animal Health (NYSE:ELAN) from a neutral rating to an overweight rating in a research report report published on Tuesday, Marketbeat.com reports. The brokerage currently has $24.00 price objective on the stock, up from their prior price objective of $18.00.

Several other brokerages have also issued reports on ELAN. William Blair raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. Wall Street Zen raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Piper Sandler raised their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, August 11th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Elanco Animal Health in a research note on Saturday, September 27th. Finally, Zacks Research raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average target price of $19.14.

Elanco Animal Health Stock Down 0.8%

Shares of NYSE ELAN opened at $20.49 on Tuesday. The firm has a market cap of $10.18 billion, a PE ratio of 23.82, a P/E/G ratio of 3.81 and a beta of 1.65. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $21.76. The company’s fifty day simple moving average is $17.98 and its 200 day simple moving average is $14.23. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. Elanco Animal Health’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, sell-side analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ELAN. Nuveen LLC bought a new position in shares of Elanco Animal Health during the first quarter valued at about $115,212,000. Dimensional Fund Advisors LP lifted its position in shares of Elanco Animal Health by 14.3% during the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after purchasing an additional 2,563,740 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Elanco Animal Health by 322.0% during the second quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock valued at $46,192,000 after purchasing an additional 2,468,122 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. bought a new position in shares of Elanco Animal Health during the first quarter valued at about $23,744,000. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.